Market research
ALEMBICLTD.NSE Alembic Limited
NSE INR Real Estate
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 22B
- P/E ratio
- 6.79
- Analyst target
- 725
- Dividend yield
- 0.0%
- Beta
- 0.68
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Real Estate
- Industry
- Real Estate - Development
- ISIN
- INE426A01027
- Market cap
- 22B
- P/E ratio
- 6.79
- Analyst target
- 725
- Dividend yield
- 0.0%
- Beta
- 0.68
About
About Alembic Limited
Alembic Limited engages in real estate business in India and internationally. It operates through Active Pharmaceutical Ingredient (API) and Real Estate segments. The company constructs residential and commercial real estate projects; provides project management and marketing consultancy services; and leases commercial properties. It also manufactures and markets fermentation and chemistry based active pharmaceutical ingredients; and research and development activities. In addition, the company is involved in power generation through co-generation plants and wind power sources. It serves individuals, entrepreneurs, corporates, business houses, HNIs, NRIs, and pharmaceutical companies. The company was incorporated in 1907 and is based in Vadodara, India. Alembic Limited is a subsidiary of Nirayu Pvt. Ltd.
Research context
Alembic Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Real Estate
- Industry
- Real Estate - Development
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ALEMBICLTD.NSE discussion.
5 years, 6 months ago
Alembic Limited is currently in a long term uptrend where the price is trading 17.9% above its 200 day moving average.
From a valuation standpoint, the stock is 1048.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 55.0.
Alembic Limited's total revenue rose by 13.5% to $145M since the same quarter in the previous year.
Its net income has increased by 25.8% to $856M since the same quarter in the previous year.
Finally, its free cash flow grew by 176.6% to $27M since the same quarter in the previous year.
Based on the above factors, Alembic Limited gets an overall score of 4/5.